| Field | Specification |
|---|---|
| Applications | |
| Molecular weight | |
| Molecular formula | C55H58N10O11S |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
MYC-RIBOTAC is a nucleic acid-targeting degrader (ribonuclease-targeting chimera, RIBOTAC) that targets the MYC internal ribosome entry site (IRES). It contains a MYC mRNA-binding component together with a small molecule that recruits and locally activates RNAse L1, and it reduces MYC mRNA and protein expression levels, induces cell apoptosis, and can be used for antitumor research[1]. It is composed of the pre-miR-155 binder Anticancer agent 167, the RNA binder NCI-B16, and the linker Amino-PEG4-alcohol. It is supplied as a light yellow to yellow solid (C55H58N10O11S, MW 1067.17) at 98.17% purity.
Physical & Chemical Properties
| Molecular Formula | C55H58N10O11S |
|---|---|
| Molecular Weight | 1067.17 g/mol |
| Purity | 98.17% |
| Appearance | Solid |
| Color | Light yellow to yellow |
| SMILES | O=C(NC1=CC(NC(NC2=CC=C(C3=NCCN3)C=C2)=O)=CC(C(NCCOCCOCCOCCOC4=C(O)C=C(/C=C5SC(NC6=CC=CC=C6)=C(C(OCC)=O)C\5=O)C=C4)=O)=C1)NC7=CC=C(C8=NCCN8)C=C7 |
| Signaling Pathway | PROTAC; Apoptosis |
| Solubility | In Vitro: DMSO: 100 mg/mL (93.71 mM; Requires sonication; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) |
| Storage | -20°C, protect from light. In solvent: -80°C, 6 months; -20°C, 1 month (protect from light). |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | 100 mg/mL (93.71 mM) | requires sonication; use freshly opened DMSO (absorbed moisture lowers solubility) |
Aliquot the stock solution and store it at -80°C (up to 6 months) or -20°C (up to 1 month); protect from light; avoid repeated freeze-thaw cycles.
Data provided by the manufacturer.
In Vitro
In HeLa cells, MYC-RIBOTAC (0-10 μM; 48 hours) lowers the abundance of MYC mRNA and protein in a dose-dependent and RNase L dependent manner[1]. In HeLa cells and Namalwa cells, MYC-RIBOTAC (0-10 μM; 48 hours) has antiproliferative and apoptosis-inducing effects[1].
Cell Proliferation Assay[1]
| Cell Line | HeLa cells and Namalwa cells |
|---|---|
| Concentration | 0-10 μM |
| Incubation Time | 48 hours |
| Result | Had antiproliferative and induce-apoptotic effects in in HeLa cells. Induced cell cycle arrest and provoked apoptosis and reduced colony formation by about 50% in Namalwa cells. |
Western Blot Analysis[1]
| Cell Line | HeLa cells |
|---|---|
| Concentration | 0-10 μM |
| Incubation Time | 48 hours |
| Result | Decreased the abundance of MYC mRNA in HeLa cells in a dose-dependent and RNase L dependent manner, up to around 50% at a 10 μM dose with a concomitant reduction in MYC protein levels. |
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
BET inhibition synergizes with RLR signaling to enhance tumor immunogenicity and T cell recognition. Cancer Immunol Res 2026 Jul 9. PMID: 42424526
bioRxiv. 2026 Feb 2.
